

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1-17. (Cancelled).

18. (New) A transmymocardial implant for defining a blood flow pathway directly from a heart chamber through a heart wall to a coronary vessel, the implant comprising:

- a coronary portion sized to be received within the vessel;
- a myocardial portion sized to pass through the myocardium; and
- a transition portion connecting the coronary portion and the myocardial portion, the transition portion defining an opening permitting bending between the coronary portion and the myocardial portion;

wherein the myocardial portion includes a lining for controlling tissue growth in the myocardial portion, and

wherein the myocardial portion includes an agent for limiting thrombus formation.

19. (New) The implant according to claim 18, wherein the lining has a length substantially equal to a width of the heart wall.

20. (New) The implant according to claim 18, wherein an axis of the coronary portion forms an angle with an axis of the myocardial portion.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

21. (New) The implant according to claim 18, wherein the myocardial portion is sized to extend into the heart chamber.

22. (New) The implant according to claim 18, wherein the coronary portion and the myocardial portion are expandable.

23. (New) The implant according to claim 18, wherein the coronary portion is expandable from a first diameter to an enlarged second diameter.

24. (New) The implant according to claim 18, wherein the myocardial portion is expandable from a first diameter to an enlarged second diameter.

25. (New) The implant according to claim 18, further comprising an agent for encouraging healing.

26. (New) The implant according to claim 25, wherein the agent for encouraging healing is a growth factor.

27. (New) The implant according to claim 18, wherein the lining contains the agent.

28. (New) The implant according to claim 18, wherein the agent is heparin.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

29. (New) The implant according to claim 18, wherein the agent is an anti-coagulant.

30. (New) The implant according to claim 18, wherein the agent is an anti-platelet.

31. (New) The implant according to claim 18, wherein the lining includes a polyester fabric.

32. (New) The implant according to claim 18, wherein the lining includes PTFE.

33. (New) The implant according to claim 18, wherein the lining is on an interior portion of the myocardial portion.

34. (New) The implant according to claim 18, wherein the transition portion includes a coil.

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER <sup>LLP</sup>

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com